AKBA
Price
$3.71
Change
+$0.03 (+0.82%)
Updated
Aug 1, 04:59 PM (EDT)
Capitalization
977.01M
97 days until earnings call
SYRE
Price
$16.26
Change
-$0.71 (-4.18%)
Updated
Aug 1, 04:59 PM (EDT)
Capitalization
981.35M
97 days until earnings call
Interact to see
Advertisement

AKBA vs SYRE

Header iconAKBA vs SYRE Comparison
Open Charts AKBA vs SYREBanner chart's image
Akebia Therapeutics
Price$3.71
Change+$0.03 (+0.82%)
Volume$71.18K
Capitalization977.01M
Spyre Therapeutics
Price$16.26
Change-$0.71 (-4.18%)
Volume$77.3K
Capitalization981.35M
AKBA vs SYRE Comparison Chart in %
Loading...
AKBA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AKBA vs. SYRE commentary
Aug 02, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AKBA is a StrongBuy and SYRE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 02, 2025
Stock price -- (AKBA: $3.69 vs. SYRE: $16.97)
Brand notoriety: AKBA and SYRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AKBA: 52% vs. SYRE: 99%
Market capitalization -- AKBA: $961.25M vs. SYRE: $1.02B
AKBA [@Biotechnology] is valued at $961.25M. SYRE’s [@Biotechnology] market capitalization is $1.02B. The market cap for tickers in the [@Biotechnology] industry ranges from $223.48B to $0. The average market capitalization across the [@Biotechnology] industry is $2.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AKBA’s FA Score shows that 0 FA rating(s) are green whileSYRE’s FA Score has 0 green FA rating(s).

  • AKBA’s FA Score: 0 green, 5 red.
  • SYRE’s FA Score: 0 green, 5 red.
According to our system of comparison, AKBA is a better buy in the long-term than SYRE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AKBA’s TA Score shows that 5 TA indicator(s) are bullish while SYRE’s TA Score has 5 bullish TA indicator(s).

  • AKBA’s TA Score: 5 bullish, 4 bearish.
  • SYRE’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, SYRE is a better buy in the short-term than AKBA.

Price Growth

AKBA (@Biotechnology) experienced а -3.91% price change this week, while SYRE (@Biotechnology) price change was -3.58% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.32%. For the same industry, the average monthly price growth was +16.82%, and the average quarterly price growth was +37.20%.

Reported Earning Dates

AKBA is expected to report earnings on Nov 06, 2025.

SYRE is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+1.32% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SYRE($981M) and AKBA($977M) have the same market capitalization . AKBA YTD gains are higher at: 94.211 vs. SYRE (-27.105). AKBA has higher annual earnings (EBITDA): 6.59M vs. SYRE (-214.36M). SYRE has more cash in the bank: 565M vs. AKBA (113M). SYRE has less debt than AKBA: SYRE (0) vs AKBA (54.1M). AKBA has higher revenues than SYRE: AKBA (185M) vs SYRE (0).
AKBASYREAKBA / SYRE
Capitalization977M981M100%
EBITDA6.59M-214.36M-3%
Gain YTD94.211-27.105-348%
P/E RatioN/A1.72-
Revenue185M0-
Total Cash113M565M20%
Total Debt54.1M0-
FUNDAMENTALS RATINGS
AKBA vs SYRE: Fundamental Ratings
AKBA
SYRE
OUTLOOK RATING
1..100
6210
VALUATION
overvalued / fair valued / undervalued
1..100
75
Overvalued
74
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10097
PRICE GROWTH RATING
1..100
3655
P/E GROWTH RATING
1..100
10081
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SYRE's Valuation (74) in the Pharmaceuticals Major industry is in the same range as AKBA (75) in the Biotechnology industry. This means that SYRE’s stock grew similarly to AKBA’s over the last 12 months.

SYRE's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as AKBA (100) in the Biotechnology industry. This means that SYRE’s stock grew similarly to AKBA’s over the last 12 months.

SYRE's SMR Rating (97) in the Pharmaceuticals Major industry is in the same range as AKBA (100) in the Biotechnology industry. This means that SYRE’s stock grew similarly to AKBA’s over the last 12 months.

AKBA's Price Growth Rating (36) in the Biotechnology industry is in the same range as SYRE (55) in the Pharmaceuticals Major industry. This means that AKBA’s stock grew similarly to SYRE’s over the last 12 months.

SYRE's P/E Growth Rating (81) in the Pharmaceuticals Major industry is in the same range as AKBA (100) in the Biotechnology industry. This means that SYRE’s stock grew similarly to AKBA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AKBASYRE
RSI
ODDS (%)
Bearish Trend 2 days ago
78%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
88%
Momentum
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
83%
MACD
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
87%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
87%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 10 days ago
85%
Declines
ODDS (%)
Bearish Trend 8 days ago
85%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
AKBA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DWOAX20.50N/A
N/A
BNY Mellon Research Growth A
AEURX8.80N/A
N/A
American Century Equity Income R
VSQFX17.98N/A
N/A
Invesco MSCI World SRI Index R5
ANTUX10.32N/A
N/A
American Century Non-US IntrsVal Inv
DILAX15.17-0.22
-1.43%
Davis International A

AKBA and

Correlation & Price change

A.I.dvisor indicates that over the last year, AKBA has been loosely correlated with XERS. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if AKBA jumps, then XERS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKBA
1D Price
Change %
AKBA100%
+0.82%
XERS - AKBA
39%
Loosely correlated
-0.68%
IPSC - AKBA
38%
Loosely correlated
-4.64%
SYRE - AKBA
37%
Loosely correlated
-1.85%
FENC - AKBA
36%
Loosely correlated
-3.63%
RXRX - AKBA
36%
Loosely correlated
-0.17%
More

SYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SYRE has been loosely correlated with IDYA. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRE jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SYRE
1D Price
Change %
SYRE100%
-1.85%
IDYA - SYRE
60%
Loosely correlated
-3.94%
CGON - SYRE
58%
Loosely correlated
+2.57%
BEAM - SYRE
58%
Loosely correlated
-2.23%
XNCR - SYRE
57%
Loosely correlated
-4.58%
CRNX - SYRE
54%
Loosely correlated
-2.26%
More